CagriSema
Cagrilintide + Semaglutide / NN9535
A fixed-ratio combination of semaglutide (GLP-1 agonist) and cagrilintide (long-acting amylin analog) co-formulated in a single weekly injection by Novo Nordisk. Targets two distinct satiety pathways simultaneously — GLP-1 in the gut/brain and amylin in the area postrema. Phase 3 REDEFINE trials show up to 25% body weight loss, rivaling bariatric surgery outcomes.
Half-life
~5–7 days (combined)
Typical Dose
2.4 mg semaglutide + 2.4 mg cagrilintide weekly
Route
subcutaneous
Category
metabolic
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How CagriSema is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 2.4 mg semaglutide + 2.4 mg cagrilintide weekly. Half-life: ~5–7 days (combined). Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
REDEFINE 1 (2025): cagrilintide 2.4 mg plus semaglutide 2.4 mg weekly gave 20.4% mean weight loss at 68 weeks versus 3.0% on placebo. Not FDA-approved.
- Novo Nordisk REDEFINE Phase 3 trial program
- Frias et al., 2023 — JAMA (CagriSema Phase 2 data)
- American Diabetes Association conference presentations
Expected to become the gold standard for pharmacological obesity treatment. Dual-mechanism approach targets both incretin and amylin pathways. Titration schedule mirrors semaglutide. GI side effects similar to but potentially worse than semaglutide alone during titration. Will likely be extremely expensive at launch.
- Obesity medicine specialist protocols
- Endocrinology conference presentations on dual-agonist therapy
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for CagriSema and 90+ other compounds with Pro.
Upgrade to ProSafety & Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Severe gastroparesis
- Pregnancy or breastfeeding
- Pancreatitis history
CagriSema: common questions
What is CagriSema?
A fixed-ratio combination of semaglutide (GLP-1 agonist) and cagrilintide (long-acting amylin analog) co-formulated in a single weekly injection by Novo Nordisk. Targets two distinct satiety pathways simultaneously — GLP-1 in the gut/brain and amylin in the area postrema. Phase 3 REDEFINE trials show up to 25% body weight loss, rivaling bariatric surgery outcomes.
How is CagriSema dosed?
CagriSema is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 2.4 mg semaglutide + 2.4 mg cagrilintide weekly. Clinical (human trials): Titrated to 2.4 mg/2.4 mg weekly; Once weekly (SubQ); 68 weeks in phase 3. Expert (practitioner protocols): Slow titration to 2.4 mg/2.4 mg weekly; Once weekly; Long-term chronic therapy. These ranges describe what has been studied or used; they are not a prescription.
Is CagriSema FDA-approved?
No. CagriSema is not FDA-approved; it is in phase 3 clinical trials.
What is the half-life of CagriSema?
DoseCraft's library lists a half-life of ~5–7 days (combined). Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use CagriSema?
Listed contraindications: Personal or family history of medullary thyroid carcinoma (MTC); Multiple endocrine neoplasia syndrome type 2 (MEN 2); Severe gastroparesis; Pregnancy or breastfeeding; Pancreatitis history.
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.